Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-positive Breast Cancer: Study 8541 from the Cancer and Leukemia Group B

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2008 Apr 9

PMID 18390970

Citations 4

Authors

Michael P DiGiovanna

David F Stern

Susan Edgerton

Gloria Broadwater

Lynn G Dressler

Daniel R Budman

I Craig Henderson

Larry Norton

Edison T Liu

Hyman B Muss

Donald A Berry

Daniel F Hayes

Ann D Thor

Affiliations

Soon will be listed here.

Abstract

Purpose: ErbB-2 (human epidermal growth factor receptor 2) overexpression may be predictive of relative resistance and/or sensitivity to specific chemotherapeutic agents. Results from a previous study from the Cancer and Leukemia Group B (CALGB 8541) demonstrated an interaction between ErbB-2 and increasing dose of adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF) chemotherapy. Other studies have suggested that evaluation of the phosphorylated/activated form of ErbB-2 might be more precise in defining the impact of ErbB-2 in breast cancer. We have evaluated tumor tissue sections from CALGB 8541 patients to determine whether the interaction of ErbB-2 with CAF dose is dependent on ErbB-2 activation state, and whether phosphorylated ErbB-2 is an adverse prognostic factor in patients treated with CAF.

Patients And Methods: Patients were randomly assigned to one of three dosing regimens of CAF. Paraffin samples from 992 of 1,572 patients who participated in CALGB 8541 were available. Of the 570 tumors with any staining for ErbB-2, 488 had tissue available for assay for phosphorylated ErbB-2, which was performed by immunohistochemistry.

Results: Of 910 total assessable cases, 112 of 488 ErbB-2-positive cases (23%) stained positively for phosphorylated ErbB-2. The previously described interaction of dosing regimen of CAF with ErbB-2 was not dependent on phosphorylation status of ErbB-2.

Conclusion: Monitoring phosphorylation of ErbB-2 with an antiphospho-ErbB-2 antibody did not add further precision to identifying those patients most likely to benefit from increased dose of anthracycline-based adjuvant chemotherapy. Favorable outcomes are observed in ErbB-2-overexpressing patients treated with high-dose CAF regardless of ErbB-2 phosphorylation state.

Citing Articles

Synthetic MRI in breast cancer: differentiating benign from malignant lesions and predicting immunohistochemical expression status.

Li X, Fan Z, Jiang H, Niu J, Bian W, Wang C Sci Rep. 2023; 13(1):17978.

PMID: 37864025 PMC: 10589282. DOI: 10.1038/s41598-023-45079-2.

Developing a Phosphospecific IHC Assay as a Predictive Biomarker for Topoisomerase I Inhibitors.

Ando K, Tohme Y, Srinivasiah A, Taylor-Parker J, Harrington Y, Shah A J Histochem Cytochem. 2018; 66(8):549-561.

PMID: 29587004 PMC: 6071180. DOI: 10.1369/0022155418766503.

Molecular predictors of response to trastuzumab and lapatinib in breast cancer.

Esteva F, Yu D, Hung M, Hortobagyi G Nat Rev Clin Oncol. 2009; 7(2):98-107.

PMID: 20027191 DOI: 10.1038/nrclinonc.2009.216.

Immunohistochemical assessment of protein phosphorylation state: the dream and the reality.

Mandell J Histochem Cell Biol. 2008; 130(3):465-71.

PMID: 18648845 PMC: 2522329. DOI: 10.1007/s00418-008-0474-z.

References

DiGiovanna M, Carter D, Flynn S, Stern D . Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. Br J Cancer. 1996; 74(5):802-6. PMC: 2074709. DOI: 10.1038/bjc.1996.439. View

Wood W, Budman D, Korzun A, Cooper M, Younger J, Hart R . Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994; 330(18):1253-9. DOI: 10.1056/NEJM199405053301801. View

Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham D . HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst. 2000; 92(24):1991-8. DOI: 10.1093/jnci/92.24.1991. View

Thor A, Berry D, Budman D, Muss H, Kute T, Henderson I . erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998; 90(18):1346-60. DOI: 10.1093/jnci/90.18.1346. View

Harris L, Yang L, Liotcheva V, Pauli S, Iglehart J, COLVIN O . Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res. 2001; 7(6):1497-504. View

Dressler L, Berry D, Broadwater G, Cowan D, Cox K, Griffin S . Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol. 2005; 23(19):4287-97. DOI: 10.1200/JCO.2005.11.012. View

Keith W, Douglas F, Wishart G, McCallum H, George W, Kaye S . Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer. 1993; 29A(10):1469-75. DOI: 10.1016/0959-8049(93)90022-8. View

DiGiovanna M, Stern D . Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Res. 1995; 55(9):1946-55. View

Muss H, Thor A, Berry D, Kute T, Liu E, Koerner F . c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994; 330(18):1260-6. DOI: 10.1056/NEJM199405053301802. View

10.

Romond E, Perez E, Bryant J, Suman V, Geyer Jr C, Davidson N . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1673-84. DOI: 10.1056/NEJMoa052122. View

11.

Thor A, Liu S, Edgerton S, Moore 2nd D, Kasowitz K, Benz C . Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol. 2000; 18(18):3230-9. DOI: 10.1200/JCO.2000.18.18.3230. View

12.

DiGiovanna M, Roussel R, Stern D . Production of antibodies that recognize specific tyrosine-phosphorylated peptides. Curr Protoc Mol Biol. 2008; Chapter 18:Unit 18.6. DOI: 10.1002/0471142727.mb1806s50. View

13.

Pritchard K, Shepherd L, OMalley F, Andrulis I, Tu D, Bramwell V . HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006; 354(20):2103-11. DOI: 10.1056/NEJMoa054504. View

14.

Yamauchi H, Stearns V, Hayes D . When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001; 19(8):2334-56. DOI: 10.1200/JCO.2001.19.8.2334. View

15.

Petit T, Borel C, Ghnassia J, Rodier J, Escande A, Mors R . Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res. 2001; 7(6):1577-81. View

16.

Hudelist G, Kostler W, Attems J, Czerwenka K, Muller R, Manavi M . Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer. 2003; 89(6):983-91. PMC: 2376939. DOI: 10.1038/sj.bjc.6601160. View

17.

Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D . erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998; 90(18):1361-70. DOI: 10.1093/jnci/90.18.1361. View

18.

Jarvinen T, Liu E . HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat. 2003; 78(3):299-311. DOI: 10.1023/a:1023077507295. View

19.

Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P . Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol. 2006; 24(16):2428-36. DOI: 10.1200/JCO.2005.02.9264. View

20.

Isaacs C, Stearns V, Hayes D . New prognostic factors for breast cancer recurrence. Semin Oncol. 2001; 28(1):53-67. DOI: 10.1016/s0093-7754(01)90045-4. View